CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lartruvo for Advanced Soft Tissue Sarcoma – Details

Project Number PC0111-000
Brand Name Lartruvo
Generic Name Olaratumab
Strength 10 mg/mL
Tumour Type Sarcoma
Indication Advanced Soft Tissue Sarcoma (STS)
Funding Request In combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and for whom treatment with an anthracycline-containing regimen is appropriate
Review Status Complete
Pre Noc Submission Yes
NOC Date November 23, 2017
Manufacturer Eli Lilly Canada Inc.
Sponsor Eli Lilly Canada Inc.
Submission Date October 26, 2017
Submission Deemed Complete November 2, 2017
Submission Type Initial
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ November 9, 2017
Check-point meeting December 13, 2017
pERC Meeting March 15, 2018
Initial Recommendation Issued March 29, 2018
Feedback Deadline ‡ April 13, 2018
Final Recommendation Issued April 18, 2018
Notification to Implement Issued May 3, 2018
Therapeutic Area Advanced Soft Tissue Sarcoma
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.